Which I consider a very healthy food
Exenatide (EC 50 = 0.60 nM, E max = 125%) and liraglutide (EC 50 = 1.8 nM, E max = 117%) were 380- and 130-fold more potent, respectively, and caused somewhat greater receptor internalization relative to PF-06882961 (Table S5)
#ObesityManagement #Semaglutide #Wegovy #HealthcareInnovation #Pharma #PatientCare To view or add a comment, sign in MetaVia's obesity treatment candidate DA-1726 demonstrates weight loss and glycemic control in Phase 1 study MetaVia, an affiliate of Dong-A ST, reported on January 6 that its Phase 1 clinical trial evaluating the maximum tolerated dose of DA-1726(development code), a glucagon-like peptide 1(GLP-1)/glucagon(GCG) dual agonist under development for the treatment of obesity, demonstrated excellent outcomes, including pronounced weight loss, improvements in glycemic control, and a decrease in liver stiffness
This is a grave condition and necessitates immediate medical attention
La Semaglutida oral es una opcin de tratamiento til para muchos pacientes con diabetes tipo 2 porque ofrece terapia GLP-1 en tableta
Action: Continue dose escalation per prescriber guidance
